Although numerous examples of evidence have demonstrated that positive PD-L1 expression is an indispensable predictive biomarker for ICI therapy, PD-L1 could not predict the efficacy of ICIs in some studies, such as nivolumab in HCC (CheckMate 040) [128,129,130]. The gene discussed is CD274; the disease is hepatocellular carcinoma.